Search

Your search keyword '"Kath, John"' showing total 147 results

Search Constraints

Start Over You searched for: Author "Kath, John" Remove constraint Author: "Kath, John"
147 results on '"Kath, John"'

Search Results

1. Addressing Quantum's 'Fine Print': State Preparation and Information Extraction for Quantum Algorithms and Geologic Fracture Networks

2. Bayesian Learning of Gas Transport in Three-Dimensional Fracture Networks

4. Reversible lysine-targeted probes reveal residence time-based kinase selectivity

6. Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes

9. Data from Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

10. Supplementary Data from Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

12. Proline-Rich Tyrosine Kinase 2 Regulates Osteoprogenitor Cells and Bone Formation, and Offers an Anabolic Treatment Approach for Osteoporosis

14. Explicit transient probabilities of various Markov models

15. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

16. Daphniphyllum alkaloids, 16. Total synthesis of (+)-codaphniphylline

18. Biomimetic total synthesis of methyl homosecodaphniphyllate: development of the tetracyclization reaction

19. A proposed biosynthesis of the pentacyclic skeleton: proto-daphniphylline

20. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

21. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

23. Chemoselective Preparation of Clickable Aryl Sulfonyl Fluoride Monomers: A Toolbox of Highly Functionalized Intermediates for Chemical Biology Probe Synthesis

24. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

25. Abstract 2594: Characterization of a novel irreversible third generation EGFR TKI that targets T790M-mediated resistant EGFR-mutant NSCLC while sparing wild type EGFR

26. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors

27. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

28. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

31. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

32. Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1)

33. Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays

36. Abstract 753: Novel, potent and selective small molecule inhibitors of 3-phosphoinositide-dependent kinase (PDK1)

38. Abstract A86: Design, synthesis, and SAR of focal adhesion kinase (FAK) inhibitors

40. Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

41. Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor

42. Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor

43. Process Development of CP-481715, a Novel CCR1 Antagonist

44. Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451

47. Novel CCR1 antagonists with improved metabolic stability

49. Potent small molecule CCR1 antagonists

50. CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases

Catalog

Books, media, physical & digital resources